Breast Cancer

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

A phase III study of Afinitor (everolimus) tablets combined with exemestane in women with breast cancer revealed that the regime significantly extended PFS.

Although researchers know that estrogen plays a role in most cases of breast cancer, they don't fully understand how.

Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits

Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings

Breast cancer survivors age 66 and older are more likely to die of cardiovascular disease (CVD) than they are of the cancer itself.

An FDA advisory committee unanimously recommended Wednesday that the agency withdraw the breast cancer indication for Avastin.

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Nearly half of older women with advanced breast cancer in the United States failed to receive radiation following a mastectomy.

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Older women with estrogen receptor (ER)-negative metastatic breast cancer have a 39% lower risk of all-cause mortality if they receive chemotherapy within 6 months of their diagnosis.

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

One issue that confronts medical oncologists is the explanation of benefits from chemotherapy

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer

Breast cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Breast imaging technology has evolved in recent years, and although the mammogram remains the gold standard for screening, researchers are excited about the possibilities of molecular breast imaging